- Oops!Something went wrong.Please try again later.
In Q4, Epizyme (NASDAQ:EPZM) posted sales of $8.38 million. Earnings were up 14.23%, but Epizyme still reported an overall loss of $62.14 million. Epizyme collected $3.57 million in revenue during Q3, but reported earnings showed a $54.40 million loss.
What Is Return On Capital Employed?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Epizyme posted an ROCE of -0.34%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Epizyme, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.
Q4 Earnings Insight
Epizyme reported Q4 earnings per share at $-0.65/share, which did not meet analyst predictions of $-0.58/share.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.